Reuters logo
BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products
August 29, 2017 / 11:04 AM / 21 days ago

BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products

Aug 29 (Reuters) - Immunogen Inc

* Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products

* Immunogen will be responsible for development of three ADC programs prior to any potential opt-in by Jazz

* Immunogen Inc - as part of agreement, Jazz will pay Immunogen an upfront payment of $75 million

* Immunogen Inc - additionally, Jazz will pay Immunogen up to $100 million in development funding over seven years to support three ADC programs

* Immunogen - After any opt-in, Jazz would be responsible for any further development as well as for potential regulatory submissions, commercialization

* Immunogen - Programs covered under agreement include IMGN779, a CD33-targeted ADC for treatment of acute myeloid leukemia (AML) in Phase 1 testing

* Immunogen - Programs under deal also include IMGN632, a CD123-targeted ADC for hematological malignancies seen to enter clinical testing before end of year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below